Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods

Last updated: September 9, 2025
Sponsor: Firalis SA
Overall Status: Active - Recruiting

Phase

N/A

Condition

Colon Cancer; Rectal Cancer

Colon Cancer

Rectal Cancer

Treatment

ONCOSCREEN

Clinical Study ID

NCT06515821
2023-A01793-42
  • Ages > 18
  • All Genders

Study Summary

The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • CRC Group
  1. Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.

  2. Subjects aged ≥18 years

  3. Subject is willing to undergo FOBT test, colonoscopy, and tissue biopsy

  4. Subject for whom the decision to perform a colonoscopy has been made by thetreating physician

  5. Subject has positive CRC diagnosis according to colonoscopy result

  6. Covered by a Health Insurance System

  7. Subject is able to comply with all study procedures

  • Control Group with risks and presence of polyps
  1. Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.

  2. Subjects aged ≥18 years

  3. Otherwise healthy individuals with recognized risk factors for CRC developmentdefined by either heredity and/or obesity and/or smoking and/or excess alcoholconsumption and/or hyperlipidaemia.

  4. Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy

  5. Subject has negative CRC diagnosis according to colonoscopy result

  6. Covered by a Health Insurance System, which will cover colonoscopy as screeningin patients with risk factors and alarm symptoms such as abdominal pain, changein stool texture, change in stool frequency, blood in stool/rectal bleeding,diarrhea, constipation, abdominal bloating, weight loss, tiredness.

  • Control Group with risks and absence of polyps
  1. Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.

  2. Subjects aged ≥18 years

  3. Otherwise healthy individuals with recognized risk factors for CRC developmentdefined by either heredity and/or obesity and/or smoking and/or excess alcoholconsumption and/or hyperlipidaemia.

  4. Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy

  5. Subject has negative CRC diagnosis according to colonoscopy result

  6. Covered by a Health Insurance System, which will cover colonoscopy as screeningin patients with risk factors and alarm symptoms such as abdominal pain, changein stool texture, change in stool frequency, blood in stool/rectal bleeding,diarrhea, constipation, abdominal bloating, weight loss, tiredness.

  • Control Group with no risks
  1. Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.

  2. Subjects aged ≥40 years

  3. Otherwise healthy individuals without any recognized risk factors for CRCdevelopment defined by either heredity and/or obesity and/or smoking and/orexcess alcohol consumption and/or hyperlipidemia.

  4. Subject be willing to undergo FOBT test

  5. Subject has negative FOBT result

Exclusion

Exclusion Criteria:

  • For the CRC Group
  1. Legal incapacity or limited legal capacity

  2. Subject did not sign the Informed Consent form

  3. Subject who, according to the investigator's assessment, presents with anunstable medical condition contraindicating the performance of the plannedblood test, stool test or breath test

  4. Subject has had surgery in the previous 6-8 weeks or is under medication forCRC treatment.

  • For the control groups
  1. Legal incapacity or limited legal capacity

  2. Subject did not sign the Informed Consent form

  3. Previous history of any type of cancer

  4. Gastrointestinal disorders or other serious acute or chronic diseases

Study Design

Total Participants: 4100
Treatment Group(s): 1
Primary Treatment: ONCOSCREEN
Phase:
Study Start date:
August 01, 2024
Estimated Completion Date:
December 31, 2026

Study Description

Colorectal Cancer (CRC) is the third most commonly occurring cancer in men and the second most commonly occurring cancer in women. CRC can often be prevented through regular screening. Although colonoscopy-based screening programs result in a significant decrease in CRC incidence, the compliance rate for performing the required screening remains too low and not the desired one. Fecal Occult Blood Test (FOBT) is another widely used screening modality for CRC but have certain constraints, such as relatively low sensitivity and the need for multiple sampling (three) to reach full screening potential. The development of novel, more practical screening methods can effectively increase the screening rates for CRC through non-invasive, repeatable, cost-effective, easy-to-use, and patient-friendly procedures. This is of particular importance in different European societies and population subgroups, since an increase in the incidence of Early-Onset CRC is currently noticed, which is significantly associated with risk factors such as heredity, obesity, smoking, alcohol abuse, and hyperlipidemia.

Within this framework, ONCOSCREEN will develop a multi-tier diagnostic solution towards improved CRC screening. Furthermore, ONCOSCREEN will consider specific socio-economic determinants which increase the regional or national CRC risks, thus exploiting new solutions, particularly in younger high-risk individuals in European communities. For the validation of the developed solution, a clinical validation study (titled "ONCOSCREEN-CS") will be conducted to assess its effectiveness, sensitivity, and specificity in detecting CRC at an early stage. During the first phase of the study (ONCOSCREEN-CS-Phase A), the investigators will identify the different expression patterns of the four diagnostic solutions (ONCO-VOC, ONCO-CRISP, ONCO-NMR, ONCO-CTC) in CRC patients and healthy controls with high risk for CRC, and also initially estimate their sensitivity and specificity. During the second phase (ONCOSCREEN-CS-Phase B), the ONCOSCREEN solution will be clinically validated.

Connect with a study center

  • University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology.

    Sofia, 1797
    Bulgaria

    Site Not Available

  • Military Medical Academy Sofia, Gastroenterology Clinic, 3 Sveti Georgi Sofiiski str., Sofia 1606, Bulgaria

    Sofia 727011, 1606
    Bulgaria

    Active - Recruiting

  • University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology.

    Sofia 727011, 1797
    Bulgaria

    Site Not Available

  • Masaryk Institute of Oncology

    Brno, 656 53
    Czechia

    Site Not Available

  • UFC: Université de Franche-Comté Oncology department CHU Besançon

    Besançon, 25030
    France

    Site Not Available

  • UFC: Université de Franche-Comté Oncology department CHU Besançon

    Besançon 3033123, 25030
    France

    Site Not Available

  • MKI UKSH Lübeck

    Lübeck, 23538
    Germany

    Site Not Available

  • MKI UKSH Lübeck

    Lübeck 2875601, 23538
    Germany

    Active - Recruiting

  • UMC Mainz: University Medical Center Mainz

    Mainz-GE, 55131
    Germany

    Site Not Available

  • UMC Mainz: University Medical Center Mainz

    Mainz-GE 8224626, 55131
    Germany

    Active - Recruiting

  • LSMU: Lithuanian University of Health Sciences Gastroenterology Department,

    Kaunas, 50161
    Lithuania

    Site Not Available

  • LSMU: Lithuanian University of Health Sciences Gastroenterology Department,

    Kaunas 598316, 50161
    Lithuania

    Active - Recruiting

  • IPO: Instituto Português de Oncologia

    Porto, 4200-072
    Portugal

    Site Not Available

  • IPO: Instituto Português de Oncologia

    Porto 2735943, 4200-072
    Portugal

    Active - Recruiting

  • IBO: Institutul Oncologic Prof. Dr. Alexandru Trestioreanu București

    Bucharest,
    Romania

    Site Not Available

  • IBO: Institutul Oncologic Prof. Dr. Alexandru Trestioreanu București

    Bucharest 683506,
    Romania

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.